基蛋生物收盘上涨1.88%，滚动市盈率21.72倍，总市值43.87亿元

Core Viewpoint - The stock of Jiedan Bio closed at 8.65 yuan, up 1.88%, with a rolling PE ratio of 21.72, marking a new low in 76 days, and a total market capitalization of 4.387 billion yuan [1] Company Summary - Jiedan Bio primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, recognized as a key high-tech enterprise under the National Torch Program [1] - The company is a major supplier in the domestic in vitro diagnostic field, particularly in the POCT sector, with its main products being self-developed POCT in vitro diagnostic reagents and supporting instruments [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross profit margin of 77.15% [1] Industry Summary - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, placing Jiedan Bio at 47th in the industry ranking [2] - The static PE ratio for Jiedan Bio is 19.62, and the price-to-book ratio is 1.63 [2] - The average market capitalization for the industry is 11.396 billion yuan, with Jiedan Bio's market cap at 4.387 billion yuan [2]